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1. Introduction 
Recently, agrowth hormone (GH) release inhibi- 
ting factor, somatostatin, was isolated from sheep hy- 
pothalamus [1]. The same authors demonstrated that, 
in man, somatostatin, besides inhibiting GH release, 
lowered basal plasma insulin levels [2]. Furthermore, 
somatostatin suppressed glucose-induced insulin re- 
lease in man [3] and in the isolated og pancreas [3]. 
The present report deals with the effect of soma- 
tostatin on glucose induced insulin release from the 
isolated perfused rat pancreas and isolated islets from 
rat pancreas. 
2. Materials and methods 
For the preparation of the perfused isolated pan- 
creas Sprague-Dawley rats weighing 200-250 g, and 
fasted for 24 hr were used. They were anesthetized 
by intraperitoneal injection of 50 mg of Pentobarbital, 
and the pancreas i olated by a slight modification of 
the technique of Loubati6res [4]. The gland was per- 
fused with a Krebs-Ringer bicarbonate solution [5], 
to which was added 1.5 g/1 of glucose and 20 g/1 of 
beef albumin. The final solution was adjusted to pH 
7.4 with 0.1 N HC1, and was continuously gassed with 
a mixture of 95% oxygen and 5% carbon dioxide. 
The perfusate was administered into the coeliac artery 
and run into the prepared pancreas by an open cir- 
cuit 'non-recycling perfusion system'. Flow rates were 
kept around 2.5 ml/min by making minor changes in 
arterial pressure. 
Preparation and incubation of pancreatic slets 
were performed according to a recently reported 
technique [6]. 
Crude collagenase was purchased from Worthing- 
ton Co., bovine albumin (fraction V) from Armour 
Co., and insulin reagent kits from the Radiochemical 
Centre, Amersham. 
Somatostatin (linear and cyclized) and rat insulin 
were generous gifts of Dr. R. Guillemin, Salk Institute, 
La Jolla, California and Dr. J. Schlichtkrull, NOVO 
Research Institute, Copenhagen, respectively. 
The effect of somatostatin o  insulin release was 
calculated by comparison of the areas under the 
insulin curves. The initial phase of insulin release was 
taken from 0-7  rain after the start of the infusion, 
while the second phase comprised the period between 
7-17 min. 
3. Results 
Increase in glucose concentration in the perfusate 
from 1.5-3.0 mg/ml was accompanied by consider- 
able insulin release from the pancreas (fig. 1). A 
typical biphasic insulin curve was obtained. The insu- 
lin level increased sharply, a peak value of 1300 
/aU/min being reached one min after the increase in 
glucose concentration in the perfusate. Insulin fell to 
a nadir at about 6 min, and then rose again during 
the remaining part of the infusion. 
Linear somatostatin i  a concentration aslow as 
one ng/ml, when infused for 10 min prior to and then 
during the infusion with 3.0 mg/ml of glucose, indu- 
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Fig. 1. Effect of linear somatostatin (1-10-100-ng/ml of perfusate) on glucose (3.0 mg/ml) induced insulin release from the isola- 
ted perfused rat pancreas. Following isolation the pancreases were equilibrated for 30 rain with 1.5 mg/ml of glucose in the per- 
fusate. The glucose stimulus was applied between 0 and 17 min, somatostatin 10 rain prior and during the glucose stimulation. 
Results are expressed as the mean -+ S. E. M. of five experiments. 
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Table 1 
Effect of somatostatin on glucose induced insulin release from isolated 
perfused rat pancreas* 
Insulin release in/~U 
Additions to 
perfusate 0 -7  min p** 7-17 p** 
Glucose (3.0 mg/ml) 3233 +- 534 7261 +- 1234 
Glucose (3.0 mg/ml) + 1866 -+ 262 < 0.05 3020 -+ 271 < 0.01 
somatostatin (1 ng/ml) 
Glucose (3.0 mg/ml) + 1785 +- 206 < 0.025 2867 +- 306 < 0.01 
somatostatin (10 ng/ml) 
* Mean -+ S.E.M. of five experiments 
** p values refer to the significance of difference of experiments with and without 
somatostatin 
Volume 42, number 2 FEBS LETTERS June 1974 
insulin 
~JUlrnin 
1000 
750 
500 
250 
0 
-1'o o ;o ~o-2'o -io ~ 1'o 2'o 
I somatos l l t ln - I lnear  I [ somatostat in-cy¢l i$  --~nin 
I olucose I I oiucose / 
Fig. 2. Comparison of the effects of linear and cyclized so- 
matos~tin (10 ng/ml) on glucose induced insulin release 
from isolated per~fused rat pancreas. For legend, see fig. 1. 
ced a significant suppression of glucose induced insu- 
lin release (fig. 1, table 1). This effect was most prom- 
inent on the second peak of the insulin curve. With 
10 ng/ml of somatostatin even the initial peak was 
clearly inhibited, and with I00 ng an almost com- 
plete inhibition of glucose induced insulin release 
was obtained. 
As seen in fig. 2, linear and cyclized somatostatins 
in a dose of 10 ng/ml of perfusate were equally effec- 
tive in suppressing glucose induced insulin release. 
When tested on isolated islets from rat pancreas, 
linear somatostatin i  concentrations up to 200 ng/nfl 
of incubation medium, had no effect on the release of 
insulin induced by 1.5 mg/ml of glucose (table 2). 
Table 2 
Effect of somatostatin (200 ng/ml) on glucose induced 
insulin release in isolated rat islets* 
Additions to medium Insulin, ~tU/islet 
Glucose (0.6 mg/ml) 2.80 -+ 0.22 
Glucose (1.5 mg/ml) 28.1 -+ 3.6 
Glucose (1.5 mg/ml) + somatostatin 30.4 -+ 6.1 
(200 ng/ml) 
* Mean ± S.E.M. of duplicates from five experiments. Incuba- 
tions were carried out for 60 rain. 
4. Discussion 
Some recent studies have suggested that the cen- 
tral nervous ystem plays a role in the control of 
insulin release from the pancreas. Thus, it has been 
demonstrated that perfusion of the hypothalamus in 
baboons with the alfa-adrenergic blocking agent, 
phentolamine, induced an enhancement of basal in- 
sulin secretion when administered in a concentration 
which had no effect when given to the systematic 
circulation [7]. Furthermore, lesions applied to the 
ventromedial nuclei of the hypothalamus were accom- 
panied by hyperinsulinemia [8]. It is still an open 
question whether these effects on insulin secretion 
were mediated by nervous routes or by humoral fac- 
tors. 
In the present study it has been clearly demon- 
strated that a newly discovered hypothalamic hor- 
mone, somatostatin, did indeed inhibit insulin secre- 
tion from the isolated perfused rat pancreas in a 
concentration aslow as one ng/ml of perfusate. This 
should be compared with the dose required for 
inhibition of GH secretion from rat pituitary cells 
in monolayer culture, 1.8 ng/ml [1]. The fact that 
such a low dose of somatostatin was that effective in 
our perfusion system might suggest that this hormone 
might be of physiological importance in the regulation 
of insulin secretion. 
The effect of somatostatin can hardly be attributed 
to impurities ince synthesized linear as well as cyclized 
somatostatin were equally effective as inhibitors of 
insulin secretion. 
A surprising finding was that somatos~atin did not 
inhibit the release of insulin from isolated rat pancrea- 
tic islets. One explanation might be that the prepara- 
tion of the islets with collagenase damages some re- 
ceptor sites for somatostatin on the beta-cell mem- 
branes. This possibility is being evaluated at present. 
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